ArticleAntioxidants (Basel, Switzerland)2023
Assessment of Cystamine's Radioprotective/Antioxidant Ability under High-Dose-Rate Irradiation: A Monte Carlo Multi-Track Chemistry Simulation Study.
Article in Antioxidants (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- TOPAS-nBio simulation of the impact of ultrahigh dose rate and oxygen concentration on the Fenton reaction using the Fricke solution.Medical physics · 2026Article
- Hyperthermal Reactions in DNA Triggered by 1-20 eV Electrons: Absolute Cross Sections for Crosslinks, Strand Breaks, Clustered Damages and Base Modifications.International journal of molecular sciences · 2025Article
- Oxygen Depletion and the Role of Cellular Antioxidants in FLASH Radiotherapy: Mechanistic Insights from Monte Carlo Radiation-Chemical Modeling.Antioxidants (Basel, Switzerland) · 2025Article
- Exploring the Metabolic Impact of FLASH Radiotherapy.Cancers · 2025Review
- Comparative Analysis of Cystamine and Cysteamine as Radioprotectors and Antioxidants: Insights from Monte Carlo Chemical Modeling under High Linear Energy Transfer Radiation and High Dose Rates.International journal of molecular sciences · 2024Article
- Effect of Linear Energy Transfer on Cystamine's Radioprotective Activity: A Study Using the Fricke Dosimeter with 6-500 MeV per Nucleon Carbon Ions-Implication for Carbon Ion Hadrontherapy.Molecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
(1) Background: cystamine and its reduced form cysteamine have radioprotective/antioxidant effects in vivo. In this study, we use an in vitro model system to examine the behavior of cystamine towards the reactive primary species produced during the radiolysis of the Fricke dosimeter under high dose-rate irradiation conditions. (2) Methods: our approach was to use the familiar radiolytic oxidation of ferrous to ferric ions as an indicator of the radioprotective/antioxidant capacity of cystamine. A Monte Carlo computer code was used to simulate the multi-track radiation-induced chemistry of aerated and deaerated Fricke-cystamine solutions as a function of dose rate while covering a large range of cystamine concentrations. (3) Results: our simulations revealed that cystamine provides better protection at pulsed dose rates compared to conventional, low-dose-rate irradiations. Furthermore, our simulations confirmed the radical-capturing ability of cystamine, clearly indicating the strong antioxidant profile of this compound. (4) Conclusion: assuming that these findings can be transposable to cells and tissues at physiological pH, it is suggested that combining cystamine with FLASH-RT could be a promising approach to further enhance the therapeutic ratio of cancer cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.